Who are Lyell Immunopharma, Inc.'s main suppliers?

Lyell Immunopharma, Inc. (LYEL) key suppliers include: Artiva Biotherapeutics, Inc., Cellectis S.A., JPMorgan Chase & Co., JPMorgan Chase & Co.. View the full supplier network at chainsifter.com/chain/LYEL.

Who are Lyell Immunopharma, Inc.'s major customers?

Lyell Immunopharma, Inc. (LYEL) key customers include: FRED-HUTCHINSON-CANCER-CENTER, JPMorgan Chase & Co., JPMorgan Chase & Co., TScan Therapeutics, Inc., COMPANY-LLC and 8 more. View the full customer network at chainsifter.com/chain/LYEL.

What sector is Lyell Immunopharma, Inc. in?

Lyell Immunopharma, Inc. (LYEL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Lyell Immunopharma, Inc. Supplier List (LYEL): 4 Verified Suppliers

4Suppliers

13Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Lyell Immunopharma, Inc. (LYEL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

2Distinct source URLs

5High confidence

0.721Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lyell Immunopharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ARTV	Artiva Biotherapeutics, Inc.	72%	Reciprocal relationship from ARTV graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and pro…
CLLS	Cellectis S.A.	72%	Reciprocal relationship from CLLS graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from CLLS g…
JPM-PD	JPMorgan Chase & Co.	72%	sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
JPM-PD	JPMorgan Chase & Co.	72%	Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from JP…

Lyell Immunopharma, Inc. Customers

Ticker	Name	Confidence	Evidence
FRED-HUTCHINSON-CANCER-CENTER	FRED-HUTCHINSON-CANCER-CENTER	92%	In 2018, the Company entered into a research and collaboration agreement with Fred Hutchinson Cancer Center, pursuant to which it granted Fred Hutch rights to certain success payments.
JPM-PD	JPMorgan Chase & Co.	72%	Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: sely affect our current and projected business operations and our financial condition and results of operations. Ad…
JPM-PD	JPMorgan Chase & Co.	72%	sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
TCRX	TScan Therapeutics, Inc.	72%	Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
COMPANY-LLC	COMPANY-LLC	62%	5, respectively. The increase of $16.6 million in other income, net was primarily driven by a gain of $17.6 million resulting from the change in the fair value of our SPA put/call asset. This gain re…
IMMPACT-BIO-USA-INC	IMMPACT-BIO-USA-INC	62%	. Consistent with the Company’s treatment of other performance-based equity awards, compensation expense is recognized for the number of shares expected to be earned after assessing the probability t…
LYELL-IMMPACT-INSPIRE-MERGER-SUB-INC	LYELL-IMMPACT-INSPIRE-MERGER-SUB-INC	62%	tionships with reliable third parties; • achieve market acceptance of our products, if any; • attract, hire and retain qualified personnel; • protect our rights in our intellectual property portfolio…
SI	Shoulder Innovations, Inc.	62%	Reciprocal relationship from SI graph: Reciprocal relationship from LYEL graph: sely affect our current and projected business operations and our financial condition and results of operations. Advers…
SILVERGATE-CAPITAL-CORP	SILVERGATE-CAPITAL-CORP	62%	sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
SONOMA-BIOTHERAPEUTICS-INC	SONOMA-BIOTHERAPEUTICS-INC	62%	try standard valuation models. Inputs utilized include market pricing based on real-time trade data for the same or similar securities and other significant inputs derived from or corroborated by obs…
SVB-SIGNATURE-BANK-SILVERGATE-CAPITAL-CORP	SVB-SIGNATURE-BANK-SILVERGATE-CAPITAL-CORP	62%	sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
USA-LLC	USA-LLC	62%	5, respectively. The increase of $16.6 million in other income, net was primarily driven by a gain of $17.6 million resulting from the change in the fair value of our SPA put/call asset. This gain re…
WT-REPRESENTATIVE-LLC	WT-REPRESENTATIVE-LLC	62%	tionships with reliable third parties; • achieve market acceptance of our products, if any; • attract, hire and retain qualified personnel; • protect our rights in our intellectual property portfolio…

Lyell Immunopharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LYEL-DEBT	Debt stack $48.9M	90%	Market cache reports total debt of $48.9M.
LYEL-DEBT-10845	Warrants outstanding: 0	90%	xbrl warrant detail from xbrl 2024-12-31.
LYEL-DEBT-10846	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Lyell Immunopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. Ownership

Holder	Name	Confidence	Evidence
LYEL-OWNER-ARCH-VENTURE-MANAGEMENT-LLC	ARCH Venture Management, LLC	90%	13F overlay lists ARCH Venture Management, LLC as top holder; 77 tracked holders.

Lyell Immunopharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IOVA	Iovance Biotherapeutics, Inc.	100.00	2
DTIL	Precision BioSciences, Inc.	100.00	2
JPM-PD	JPMorgan Chase & Co.	100.00	1	['customer', 'supplier']
RNAC	Cartesian Therapeutics, Inc.	100.00	2
KYTX	Kyverna Therapeutics, Inc.	100.00	2
NVSEF	Novartis AG	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
TMO	Thermo Fisher Scientific Inc.	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
NTLA	Intellia Therapeutics, Inc.	100.00	2
AUTL	Autolus Therapeutics plc	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
SI	Shoulder Innovations, Inc.	100.00	1	['customer']
IPSC	Century Therapeutics, Inc.	100.00	2
CINF	Cincinnati Financial Corporation	50.00	2
CAN	Canaan Inc.	50.00	2

Lyell Immunopharma, Inc. Supply Chain